Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLAfit vs Fremanezumab for Migraine Prevention
NCT04547179Unknown
- Sponsor
- Manhattan Beach Orthodontics
- Start
- Feb 2021
- Primary completion
- Apr 2021
- Countries
- 1
01
Overview
Randomised, double-blind trial (3 arms), sponsored by Manhattan Beach Orthodontics. Primary endpoints: Frequency of Migraines Post-Treatment at 4 months and Pain Level of Migraines Post-Treatment at 4 months. Status: unknown.
Beyond the preview
Go deeper on NCT04547179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04547179.